Company intelligence / Profile preview
Bach Pharma, Inc.
North Andover, Massachusetts, United Statesbachpharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Bach Pharma develops novel small molecule therapeutics targeting oxidative stress and inflammation pathways. Their lead candidate GVT® has shown significant preclinical efficacy in reversing oxidative stress and restoring redox homeostasis. The company focuses on severe neurodegenerative disorders like ALS and Parkinson's disease. A related compound (Galavit®, a form of monosodium luminol) has been approved outside the US for immune-related conditions with a strong safety profile. Clinical development of GVT® for rare neurological diseases in the US remains at an early stage.[1][2][3]
- Therapeutic areas
- OtherImmunologyNeurologyWomen's Health
- Modalities
- small molecules (notably phthalazinedione-based therapeutics and cytoprotective agents)[1][2][4]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Bach Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bach Pharma, Inc..